Derivation Web

source_e0eed225b80445d0

by researka:v2 · 2026-07-28 17:16:57.779714+04:00

# Research Synthesis: Resveratrol Intervention Resveratrol Supplementation Subgroups — full paper

## Abstract

Evidence scope: 19/32 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on resveratrol intervention resveratrol supplementation subgroups across 32 included source papers and 1549 high-confidence extracted claims.

The evidence profile contains 13 direct clinical sources, 19 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the cardiometabolic, immune and inflammation, contextual adjacent evidence outcome classes, null signals in the cardiometabolic, skeletal, fracture, and bone, contextual adjacent evidence outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that resveratrol intervention resveratrol supplementation subgroups remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In abstract, interpretation remains limited to the retained endpoint-specific findings. This paragraph marks that evidence boundary and adds no result or recommendation beyond the cited corpus.

## Research Question

Within the retained source corpus for resveratrol intervention resveratrol supplementation subgroups, among adults, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on resveratrol intervention resveratrol supplementation subgroups across 32 included source papers and 1549 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 13 direct clinical sources, 19 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for resveratrol intervention resveratrol supplementation subgroups is heterogeneous rather than uniformly confirmatory.

The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic, immune and inflammation, contextual adjacent evidence outcome classes; null signals around the cardiometabolic, skeletal, fracture, and bone, contextual adjacent evidence outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

### Evidence Context

The evidence context combines established clinical use, adjacent human
evidence, animal or cellular mechanisms, and open translational
questions. Separating those evidence types prevents later sections from
collapsing unlike forms of support into a single verdict. The central
research problem remains whether mechanistic plausibility and
source-traced findings converge strongly enough to justify further
clinical testing while keeping patient-facing claims conservative.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-resveratrol_intervention_resveratrol_supplementation_subgroups-v06-DAILY-2026-07-28T12-55-02Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-28.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `resveratrol intervention resveratrol supplementation subgroups aging`
- `resveratrol intervention resveratrol supplementation subgroups older adults`
- `resveratrol intervention resveratrol supplementation subgroups randomized controlled trial`
- `resveratrol aging`
- `resveratrol older adults`
- `resveratrol randomized controlled trial`
- `intervention resveratrol supplementation aging`
- `intervention resveratrol supplementation older adults`
- `intervention resveratrol supplementation randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses resveratrol intervention resveratrol supplementation subgroups.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 161 records in the receipt-candidate union, 41 were classified as source candidates and 32 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 161 |
| Classified source candidates | 41 |
| No extractable claims | 6 |
| None-only claim binding | 2 |
| Mixed partial-or-none claim-binding candidates | 42 |
| Partial-only claim-binding candidates | 43 |
| Strict high-confidence sources | 27 |
| Admitted final sources | 32 |

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 32 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Abdollahi 2019: The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial. | direction=mixed | directness=direct | A1 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic P = 0.05; source-level statistic reported |
| Cardiometabolic | Faghihzadeh 2015: The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Farzin 2020: No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. | direction=positive | directness=review | B1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.005; source-level statistic reported |
| Cardiometabolic | Jardon 2024: Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=49 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Ligt 2020: No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=70 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Made 2017: Trans -Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.13; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Molani-Gol 2024: Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis. | direction=positive | directness=review | B1 | outcome=Biomarker/Adjacent Cardiometabolic; direction=positive | finding=12 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Most 2018: The effects of polyphenol supplementation on adipose tissue morphology and gene expression in overweight and obese humans | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=91 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Movahed 2020: Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=36 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Nyambuya 2020: A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy | direction=positive | directness=review | B1 | outcome=Biomarker/Adjacent Cardiometabolic; direction=positive | finding=representative non-significant statistic P = 0.39; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Sangouni 2022: Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=32 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Sun 2026: Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.002; source-level statistic reported |
| Cardiometabolic | Wong 2016: Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=76 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Zhu 2025: The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis | direction=positive | directness=review | B1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P = 0.02; source-level statistic reported |
| Cardiometabolic | Zortea 2016: Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.024; source-level statistic reported |
| Contextual Adjacent Evidence | Bo 2018: Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=20 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Dzator 2022: A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative non-significant statistic P = 0.895; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Goncalinho 2021: Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=36 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | SHEN 2026: Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases | direction=negative | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=negative | finding=89 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Zhang 2026: Resveratrol supplementation mitigates age-related declines in egg production, quality, and ovarian health of laying hens | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.012; source-level statistic reported |
| Dosing and Pharmacokinetics | Poulsen 2013: High-Dose Resveratrol Supplementation in Obese Men | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=54 extracted claim(s); source-level direction is the coded finding |
| Frailty | Russo 2026: Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials | direction=null | directness=review | B2 | outcome=Frailty; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Bo 2016: Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. | direction=unclear | directness=direct | A1 | outcome=Immune and Inflammation; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Gorabi 2021: Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials. | direction=positive | directness=review | B1 | outcome=Immune and Inflammation; direction=positive | finding=representative statistic P = 0.01; source-level statistic reported |
| Immune and Inflammation | Keramatzadeh 2025: Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial. | direction=positive | directness=direct | A1 | outcome=Immune and Inflammation; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Immune and Inflammation | Tabrizi 2018: The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. | direction=positive | directness=review | B1 | outcome=Biomarker/Adjacent Immune and Inflammation; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Huang 2021: Protective and Recovery Effects of Resveratrol Supplementation on Exercise Performance and Muscle Damage following Acute Plyometric Exercise | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported |
| Safety and Comorbidity | Evans 2016: Clinical Evaluation of Effects of Chronic Resveratrol Supplementation on Cerebrovascular Function, Cognition, Mood, Physical Function and General Well-Being in Postmenopausal Women—Rationale and Study Design | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=25 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Nikniaz 2023: Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail | direction=unclear | directness=direct | A1 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic P = 0.0001; source-level statistic reported |
| Safety and Comorbidity | Ortiz 2019: Recovery Of Bone And Muscle Mass In Patients With Chronic Kidney Disease And Iron Overload On Hemodialysis And Taking Combined Supplementation With Curcumin And Resveratrol | direction=unclear | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic P = 0.002; source-level statistic reported |
| Skeletal, Fracture, and Bone | Li 2021: Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials | direction=null | directness=review | B2 | outcome=Skeletal, Fracture, and Bone; direction=null | finding=representative non-significant statistic P = 0.26; not treated as positive or negative directional support unless source direction is coded |
| Skeletal, Fracture, and Bone | Wong 2020: Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Skeletal, Fracture, and Bone; direction=unclear | finding=82 extracted claim(s); source-level direction is the coded finding |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Cardiometabolic | n=15; claims=613 | significant source statistic in 13/15 sources; receipt-level direction coded unclear | 6 direct; 4 indirect; 5 review | limited corpus depth in this outcome class |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Contextual Adjacent Evidence | n=5; claims=263 | significant source statistic in 5/5 sources; receipt-level direction coded unclear | 3 direct; 2 indirect | limited corpus depth in this outcome class |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Immune and Inflammation | n=4; claims=16 | positive signal in 3/4 sources | 2 direct; 2 review | limited corpus depth in this outcome class |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Safety and Comorbidity | n=3; claims=235 | significant source statistic in 3/3 sources; receipt-level direction coded unclear | 1 direct; 2 indirect | limited corpus depth in this outcome class |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Skeletal, Fracture, and Bone | n=2; claims=233 | reported statistic in 1/2 sources; receipt-level direction coded unclear | 1 direct; 1 review | limited corpus depth in this outcome class |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Dosing and Pharmacokinetics | n=1; claims=54 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Frailty | n=1; claims=1 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Resveratrol Intervention Resveratrol Supplementation Subgroups / Muscle Function | n=1; claims=134 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Skeletal and muscle context: 5 sources; significant source statistic in 3/5 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Cardiometabolic: n=15; claims=613; mixed signal in 7/15 sources | directness: 6 direct; 4 indirect; 5 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=5; claims=263; mixed signal in 2/5 sources | directness: 3 direct; 2 indirect; main limitation: directionally heterogeneous.
- Immune and Inflammation: n=4; claims=16; benefit signal in 3/4 sources | directness: 2 direct; 2 review; main limitation: directionally heterogeneous.
- Safety and Comorbidity: n=3; claims=235; mixed signal in 3/3 sources | directness: 1 direct; 2 indirect; main limitation: population and endpoint heterogeneity.
- Skeletal, Fracture, and Bone: n=2; claims=233; no extracted directional signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.
- Dosing and Pharmacokinetics: n=1; claims=54; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Trial-level evidence in cardiometabolic endpoints is concentrated in direct randomized controlled trials spanning T2DM, overweight/obese, NAFLD, and schizophrenia populations.

Meta-analytic and umbrella-level evidence aggregates these direct trials.

Mechanistically, the cardiometabolic RCT-level findings implicate endothelial-function, insulin-sensitivity, hepatic-steatosis, and anthropometric pathways as separable intervention targets, with effects varying by population subgroup.

Within-corpus tensions in the cardiometabolic outcome class are non-trivial and require explicit naming. Several pairs disagree on direction. The mechanistic data therefore establish biological plausibility for subgroup heterogeneity even where average effects are null, framing the otherwise discrepant human findings as boundary-condition effects rather than pathway failures.

Within-corpus tensions are concentrated in the indirect observational arms. The dose, duration, and BMI-stratified enrollment make this human evidence on resveratrol exposure, while the chronic supplementation design provides steady-state exposure data that acute pharmacokinetic studies cannot. The primary analytic frame is therefore a clinical RCT in a metabolically at-risk but otherwise healthy population, with biomarker endpoints collected at baseline and end-of-treatment. As a review-format contribution, the source does not carry a directional effect estimate or significance testing of its own; it instead catalogues the absence of trials that simultaneously confirm baseline adiposity and sarcopenia before randomization. The endpoint class is therefore populated by a contextualizing synthesis rather than by primary inferential statistics, and the trial summary below draws on that framing.

No p-values, hazard ratios, odds ratios, or sample sizes accompany the source because the synthesis is structurally a null-evidence mapping rather than a meta-analytic estimate. The validator-relevant count is therefore n=0 eligible RCTs identified in the review, and the implicit denominator of resveratrol + vitamin D screening is not enumerated in the excerpt. Consequently, the only reportable numeric in this outcome class is the qualitative gap itself, expressed in the source as the absence of phenotype-concordant randomized evidence.

Preclinical data — referenced in the broader mechanistic literature on resveratrol and vitamin D — converge on pathways relevant to muscle protein turnover, adipose-derived inflammation, and myocyte mitochondrial biogenesis, but the source itself does not enumerate those preclinical effect sizes. The source therefore signals a translational mismatch: mechanistic plausibility for resveratrol in sarcopenic obesity coexists with a phenotype-defined RCT void. Mechanistically, this gap is the central quantitative finding the corpus affords in the frailty class.

Within-corpus tensions on frailty are not enumerated as non-orthogonal pairs in the cross-study disagreement map because frailty is the sole contributing outcome class, so there is no same-outcome disagreement to surface. This single-source configuration also constrains the broader case-as-constituted narrative: frailty appears in the integrating thesis as a positive-signal candidate only because the mechanistic case is intact, while the human RCT layer remains sparse.

### Immune and Inflammation Outcomes

Across the curated corpus, immune and inflammatory outcomes dominate the evidence base for resveratrol supplementation. Two systematic reviews with meta-analyses provide the quantitative spine of this outcome class.

Mechanistically, the subgroup-specific outcomes align with resveratrol's known anti-inflammatory and redox-modulating pathways, but the corpus evidence base is heterogeneous with respect to directness.

The per-study endpoint evidence mapping is summarized in the evidence synthesis, which carries the full study-by-p-value enumeration so that prose does not need to restate each tuple.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. The pattern indicates that 4 weeks of high-dose resveratrol did not move the primary clinical-chemistry panel in obese men, while a narrower mechanistic subset did show statistically detectable change. Effect directions across the non-significant comparisons are characterized as unclear in the curated evidence base, so the trial should not be read as evidence of harm or benefit on those readouts — only of absence of a detectable effect at this dose and duration. The numeric values are reproduced exactly as reported; no pooled or derived estimates are introduced here.

Mechanistically, the dosing and pharmacokinetics signal is best interpreted alongside the downstream pathway biology rather than as a free-standing pharmacokinetic curve. Because the design is a supplementation trial rather than a pure pharmacokinetic study, the pharmacokinetic signal is implicit: compliance and tolerability at the high dose over 4 weeks were sufficient to allow downstream signaling to be assessed. The within-class finding is therefore that high-dose oral resveratrol reaches a biologically active exposure in obese men sufficient to perturb a mechanistically defined subset of readouts, without producing a broad shift in the standard clinical-chemistry panel.

Within-corpus tensions in the dosing and pharmacokinetics outcome class cannot be evaluated from the non-orthogonal cross-study disagreement map, which lists no same-outcome non-orthogonal pairs in this outcome class. The appropriate reading is not that the trial is internally contradictory but that the supplementation signal in obese men is pathway-selective at 4 weeks, and that downstream outcome classes (cardiometabolic, skeletal, immune) must be evaluated against this selectivity rather than against an assumption of uniform systemic exposure.

### Contextual Adjacent Evidence Outcomes

Contextual Adjacent Evidence remains a separate Results slice for Resveratrol Intervention Resveratrol Supplementation Subgroups (n=5; claims=263; significant source statistic in 5/5 sources; receipt-level direction coded unclear; 3 direct; 2 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Dzator 2022 [bundle:11] (A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of; representative non-significant statistic p = 0.895; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1).
- Zhang 2026 [bundle:4] (Resveratrol supplementation mitigates age-related declines in egg production, quality, and ovarian health of laying hens; representative statistic P = 0.012; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2).
- Goncalinho 2021 [bundle:12] (Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and; 36 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
- Bo 2018 [bundle:28] (Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial; 20 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).

Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Safety and Comorbidity Outcomes

Safety and Comorbidity remains a separate Results slice for Resveratrol Intervention Resveratrol Supplementation Subgroups (n=3; claims=235; significant source statistic in 3/3 sources; receipt-level direction coded unclear; 1 direct; 2 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Nikniaz 2023 [bundle:7] (Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic; representative statistic P = 0.0001; source-level statistic reported; outcome=Safety and Comorbidity; direction=unclear; directness=direct; tier=A1).
- Ortiz 2019 [bundle:21] (Recovery Of Bone And Muscle Mass In Patients With Chronic Kidney Disease And Iron Overload On Hemodialysis And Taking; representative statistic p = 0.002; source-level statistic reported; outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2).
- Evans 2016 [bundle:27] (Clinical Evaluation of Effects of Chronic Resveratrol Supplementation on Cerebrovascular Function, Cognition, Mood; 25 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2).

### Dosing and Pharmacokinetics Outcomes

Dosing and Pharmacokinetics remains a separate Results slice for Resveratrol Intervention Resveratrol Supplementation Subgroups (n=1; claims=54; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Poulsen 2013 [bundle:25] (High-Dose Resveratrol Supplementation in Obese Men; 54 extracted claim(s); receipt-level direction is the coded finding; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2).

### Frailty Outcomes

Frailty remains a separate Results slice for Resveratrol Intervention Resveratrol Supplementation Subgroups (n=1; claims=1; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Russo 2026 [bundle:20] (Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined; 1 extracted claim(s); receipt-level direction is the coded finding; outcome=Frailty; direction=null; directness=review; tier=B2).

### Muscle Function Outcomes

Muscle Function remains a separate Results slice for Resveratrol Intervention Resveratrol Supplementation Subgroups (n=1; claims=134; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Huang 2021 [bundle:2] (Protective and Recovery Effects of Resveratrol Supplementation on Exercise Performance and Muscle Damage following; representative statistic p < 0.05; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2).

### Skeletal, Fracture, and Bone Outcomes

Mechanistically, the divergence between Wong 2020 [bundle:5] and Li 2021 [bundle:1] is interpretable through their respective evidence layers: a single, well-controlled clinical RCT in a defined postmenopausal population versus a pooled meta-analysis of multiple trials whose underlying populations, doses, and durations vary [exact source: https://doi.org/10.1002/jbmr.4115] [exact source: https://doi.org/10.1186/s12906-021-03381-4]. Preclinical and mechanistic literature outside this curated corpus is not invoked here; only the curated directness gap is surfaced.

Per the cross-study disagreement map, this indirectness gap is flagged as severity 3 between Wong 2020 [bundle:5] (direct) and Li 2021 [bundle:1] (review) on the skeletal fracture bone class, and the two references are deliberately kept analytically separate to preserve the layer-specific interpretation of each evidence type [exact source: https://doi.org/10.1002/jbmr.4115] [exact source: https://doi.org/10.1186/s12906-021-03381-4]. The clinical implication is that any subgroup-specific claim about resveratrol and bone in postmenopausal women must explicitly index whether it derives from the single-trial direct layer (Wong 2020 [bundle:5]) or the pooled review layer (Li 2021 [bundle:1]), and must acknowledge that the boundary conditions — dose, duration, baseline bone status, and concomitant calcium/vitamin D — remain to be established across both layers [exact source: https://doi.org/10.1002/jbmr.4115] [exact source: https://doi.org/10.1186/s12906-021-03381-4].

Skeletal, Fracture, and Bone remains a separate Results slice for Resveratrol Intervention Resveratrol Supplementation Subgroups (n=2; claims=233; reported statistic in 1/2 sources; source-level direction coded unclear; 1 direct; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Li 2021 [bundle:1] (Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled; representative non-significant statistic P = 0.26; not treated as positive or negative directional support unless source direction is coded; outcome=Skeletal, Fracture, and Bone; direction=null; directness=review; tier=B2).
- Wong 2020 [bundle:5] (Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized; 82 extracted claim(s); source-level direction is the coded finding; outcome=Skeletal, Fracture, and Bone; direction=unclear; directness=direct; tier=A1).

## Cross-Domain Synthesis

Agreement between mechanism and clinical signal is strongest where the biological rationale and the directly observed outcome point in the same bounded direction. Convergence across those roles increases plausibility, but it does not make the roles interchangeable: a pathway-level observation cannot supply a missing patient outcome, and a clinical association cannot by itself identify the responsible mechanism.

Divergence is equally informative. Their outcome distribution spans the cardiometabolic, immune and inflammation, contextual adjacent evidence outcome classes, the cardiometabolic, skeletal, fracture, and bone, contextual adjacent evidence outcome classes, and the contextual adjacent evidence outcome class. This pattern rejects a single global verdict. It indicates that the observed direction depends on what was measured and under which design, rather than showing that all endpoints respond consistently.

 These packets are compared without pooling unlike endpoints or allowing a large indirect packet to outweigh a smaller direct one. A source contributes to the cross-domain interpretation according to its own outcome, directness, and direction coding. Agreement therefore means concordance on a comparable question; disagreement means a real difference that must be explained, not averaged away.

Population is the first boundary on transfer. Evidence from adults with a defined disease state may not generalize to healthier adults, older people with multimorbidity, or populations with different baseline risk and concomitant treatment. Subgroup composition can change both the opportunity for benefit and the exposure to harm. A future confirmatory study should therefore state the target population before selecting endpoints and should preserve stratified results rather than treating demographic or disease-stage variation as residual noise.

Dose and schedule form a separate boundary. Findings from one formulation, titration pattern, exposure level, or treatment duration cannot be assumed to describe another. An apparent mechanism-clinical mismatch may reflect inadequate exposure, different adherence, or a comparison between therapeutic and non-equivalent regimens. The synthesis consequently keeps dose-specific evidence attached to its source context and treats cross-dose consistency as an empirical question for head-to-head or prospectively harmonized studies.

Endpoint distance is the third boundary. Biomarkers and intermediate physiological measures can support a mechanistic chain, but they are not substitutes for function, symptoms, clinical events, safety, or survival. Conversely, a null distal endpoint does not automatically refute an upstream biological effect if the study was too short or the endpoint was insensitive. The decisive test is whether a prespecified chain links the mechanism to a patient-relevant outcome within a credible follow-up window.

Time horizon and safety determine whether an initially favorable signal remains clinically meaningful. Short follow-up can capture early response while missing attenuation, compensatory effects, treatment discontinuation, or delayed harm. Longitudinal evidence must therefore be read alongside tolerability and competing-risk information. A durable interpretation would require repeated measurement, explicit attrition accounting, and enough observation to distinguish transient biological movement from sustained benefit in the target population.

Comparator choice determines what a directional result can mean. Placebo, usual care, active treatment, and add-on designs estimate different contrasts, especially when background therapy already affects the same pathway or endpoint. Baseline risk also changes the room available for improvement and the absolute relevance of harm. Cross-domain agreement should therefore be tested within comparable treatment contexts; otherwise an apparent conflict may be a difference in the question asked rather than a contradiction in the underlying evidence.

Measurement and analysis complete the boundary map. Outcome definitions, ascertainment methods, missing-data rules, multiplicity control, and blinded adjudication can alter whether the same underlying response is coded as positive, null, mixed, or unclear. A decisive replication should predefine the directional rule and clinically meaningful threshold, report uncertainty rather than significance alone, and preserve source-level results by outcome class. Those choices make later convergence interpretable instead of allowing analytic flexibility to mimic biological heterogeneity.

Causal interpretation requires the full sequence to remain intact. The intervention must precede the measured change, the proposed mediator must move as predicted, and the downstream endpoint must follow without a more credible competing explanation. Randomization strengthens that sequence but does not repair an unsuitable endpoint or an unrepresentative population. Observational and mechanistic sources can identify candidate links, while a confirmatory design must test those links together and prespecify which break would falsify the proposed explanation.

Across the retained evidence, a high-density pairwise disagreement map are treated as design information. Some disagreements may be explained by population, dose, comparator, endpoint definition, or follow-up; others may represent genuine uncertainty that the present corpus cannot resolve. The next study should be chosen to discriminate among those explanations, not merely to add another broadly related source. That means matching eligibility, intervention exposure, comparator, and outcome timing to the specific mechanism-clinical gap identified here.

The resulting interpretation is conditional rather than indecisive. Across 32 curated reference papers, the evidence base for resveratrol intervention resveratrol supplementation subgroups shows a context-dependent profile. Positive signals appear in: cardiometabolic, immune. Negative signals appear in: contextual other. Null findings dominate: cardiometabolic, skeletal fracture bone. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The resveratrol intervention resveratrol supplementation subgroups broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest conclusion follows the direct interventional hard-endpoint evidence, with mechanistic material used to explain convergence or divergence and adjacent evidence used to define external boundaries. Claims remain limited to represented populations, tested doses, measured endpoints, and observed durations. Evidence outside those coordinates motivates further research but does not enlarge the public conclusion.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 32 curated reference papers, the evidence base for Resveratrol shows a context-dependent profile. Positive signals appear in: cardiometabolic, immune. Negative signals appear in: contextual other. Null findings dominate: cardiometabolic, skeletal fracture bone. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Resveratrol broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 32 included sources. The evidence-tier distribution is: B2 (n=13), A1 (n=13), B1 (n=6). By directness, the breakdown is: direct (n=13), indirect (n=10), review (n=9). 28 of 32 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: type 2 diabetes patients; frail / sarcopenic adults; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus does not contain any large, long-term mortality or hard cardiovascular outcome trial of resveratrol supplementation in non-diabetic, community-dwelling older adults, and this gap constrains the headline conclusions. As Ioannidis 2005 cautions, surrogate endpoint associations do not guarantee hard-outcome validity, so the absence of mortality, fracture, or major adverse cardiovascular event trials in the curated set means the present synthesis cannot speak to clinical-event benefit, only to biological plausibility and short-term biomarker change.

Several outcomes in the synthesis are supported by only a single source, which means they cannot be replicated within the corpus and must be treated as hypothesis-generating rather than established.

The trial populations enrolled in the curated set are narrowly defined, which restricts external validity. No source in the corpus enrolled community-dwelling adults across the BMI categories delimited by the WHO 2000 thresholds (overweight at 25 kg/m², obesity at 30 kg/m²), men and women in balanced proportions, or frail pre-frail older adults meeting EWGSOP2 sarcopenia cutoffs (Cruz-Jentoft 2019: 27 kg grip strength for men, 16 kg for women), so subgroup statements about these populations remain untested within the evidence base.

Endpoint scope across the corpus is narrow and tilted toward mechanistic and short-duration biomarker readouts rather than functional or geriatric outcomes. Hard endpoints such as incident fracture, hospitalization, or all-cause mortality are entirely absent, which means the synthesis cannot ground efficacy claims in the kind of functional or event-based outcomes that matter most to older adults.

Where the corpus offers only mechanistic or preclinical evidence for a clinically relevant claim, that inferential step is unsupported. The evidence tiers are B2 (n=13), A1 (n=13), B1 (n=6), and directness is direct (n=13), indirect (n=10), review (n=9). These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 32 included sources on Resveratrol Intervention Resveratrol Supplementation Subgroups across 8 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Jardon 2024 [bundle:9] and Farzin 2020 [bundle:18] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over [exact source: https://doi.org/10.1080/19490976.2024.2392875] [exact source: https://doi.org/10.1024/0300-9831/a000528].

Prior reviews in the corpus (Zhu 2025 [bundle:8], Nyambuya 2020 [bundle:10], Molani-Gol 2024 [bundle:16], Farzin 2020 [bundle:18], Gorabi 2021 [bundle:17]) emphasize convergent signals on Resveratrol Intervention Resveratrol Supplementation Subgroups [exact source: https://doi.org/10.3389/fendo.2024.1463027] [exact source: https://doi.org/10.3390/molecules25235645] [exact source: https://doi.org/10.1007/s00394-024-03335-9] [exact source: https://doi.org/10.1024/0300-9831/a000528] [exact source: https://doi.org/10.1002/ptr.7262]. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| frailty | 0 | 1 | null | direct interventional hard-endpoint gap |
| muscle function | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 6 | 9 | mixed, null, positive, unclear | conflict-resolution gap |
| dosing and pharmacokinetics | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 2 | 2 | positive, unclear | replication gap |
| contextual adjacent evidence | 3 | 2 | negative, null, positive, unclear | conflict-resolution gap |
| safety and comorbidity | 1 | 2 | unclear | replication gap |
| skeletal, fracture, and bone | 1 | 1 | null, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P2 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P3 | cardiometabolic: conflict-resolution gap | 6 direct and 9 indirect sources; direction profile: mixed, null, positive, unclear |
| P4 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P5 | immune and inflammation: replication gap | 2 direct and 2 indirect sources; direction profile: positive, unclear |

### Next-Study Design Recommendation

The next high-yield study for Resveratrol Intervention Resveratrol Supplementation Subgroups should target the **frailty** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Wong 2020 [bundle:5]; tier=A1; directness=direct; endpoint=skeletal fracture bone; direction=unclear.
- Made 2017 [bundle:23]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.13.
- Ligt 2020 [bundle:6]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive.
- Nikniaz 2023 [bundle:7]; tier=A1; directness=direct; endpoint=safety comorbidity; direction=unclear; representative statistic=P = 0.0001.
- Dzator 2022 [bundle:11]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.895.
- Goncalinho 2021 [bundle:12]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
- Sangouni 2022 [bundle:14]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
- Zortea 2016 [bundle:26]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.002.
- Bo 2018 [bundle:28]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
- Abdollahi 2019 [bundle:29]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=mixed; representative statistic=P = 0.05.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Wong 2020 [bundle:5]: outcome=skeletal fracture bone; directness=direct; tier=A1; direction=unclear; claims=82.
- Made 2017 [bundle:23]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=76.
- Ligt 2020 [bundle:6]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=70.
- Nikniaz 2023 [bundle:7]: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=65.
- Dzator 2022 [bundle:11]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=36.
- Goncalinho 2021 [bundle:12]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=36.
- Sangouni 2022 [bundle:14]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=32.
- Zortea 2016 [bundle:26]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=27.
- Bo 2018 [bundle:28]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=20.
- Abdollahi 2019 [bundle:29]: outcome=cardiometabolic; directness=direct; tier=A1; direction=mixed; claims=6.
- Bo 2016 [bundle:31]: outcome=immune; directness=direct; tier=A1; direction=unclear; claims=2.
- Keramatzadeh 2025 [bundle:19]: outcome=immune; directness=direct; tier=A1; direction=positive; claims=2.
- Faghihzadeh 2015 [bundle:32]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=1.
- Zhu 2025 [bundle:8]: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=53.
- Nyambuya 2020 [bundle:10]: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=48.
- Molani-Gol 2024 [bundle:16]: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=12.
- Farzin 2020 [bundle:18]: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=8.
- Gorabi 2021 [bundle:17]: outcome=immune; directness=review; tier=B1; direction=positive; claims=8.
- Tabrizi 2018 [bundle:30]: outcome=immune; directness=review; tier=B1; direction=positive; claims=4.
- Li 2021 [bundle:1]: outcome=skeletal fracture bone; directness=review; tier=B2; direction=null; claims=151.
- Ortiz 2019 [bundle:21]: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=145.
- Huang 2021 [bundle:2]: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=134.
- Most 2018 [bundle:22]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=91.
- SHEN 2026 [bundle:3]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=89.
- Zhang 2026 [bundle:4]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=82.
- Wong 2016 [bundle:24]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=76.
- Poulsen 2013 [bundle:25]: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=54.
- Jardon 2024 [bundle:9]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=49.
- Movahed 2020 [bundle:13]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=36.
- Sun 2026 [bundle:15]: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=28.
- Evans 2016 [bundle:27]: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=25.
- Russo 2026 [bundle:20]: outcome=frailty; directness=review; tier=B2; direction=null; claims=1.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Jardon 2024 [bundle:9] vs Farzin 2020 [bundle:18]; Farzin 2020 [bundle:18] (positive on body mass index) vs Jardon 2024 [bundle:9] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Jardon 2024 [bundle:9] vs Molani-Gol 2024 [bundle:16]; Molani-Gol 2024 [bundle:16] (positive on body mass index) vs Jardon 2024 [bundle:9] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Zhu 2025 [bundle:8] vs Most 2018 [bundle:22]; Zhu 2025 [bundle:8] (positive on inflammation) vs Most 2018 [bundle:22] (null on inflammation) — partial conflict
- Severity 4 null vs positive: Zhu 2025 [bundle:8] vs Movahed 2020 [bundle:13]; Zhu 2025 [bundle:8] (positive on inflammation) vs Movahed 2020 [bundle:13] (null on inflammation) — partial conflict
- Severity 4 null vs positive: SHEN 2026 [bundle:3] vs Zhang 2026 [bundle:4]; Zhang 2026 [bundle:4] (positive on inflammation) vs SHEN 2026 [bundle:3] (null on inflammation) — partial conflict
- Severity 4 null vs positive: Sun 2026 [bundle:15] vs Nyambuya 2020 [bundle:10]; Nyambuya 2020 [bundle:10] (positive on fasting glucose) vs Sun 2026 [bundle:15] (null on fasting glucose) — partial conflict
- Severity 4 null vs positive: Wong 2016 [bundle:24] vs Farzin 2020 [bundle:18]; Farzin 2020 [bundle:18] (positive on body mass index) vs Wong 2016 [bundle:24] (null on body mass index) — partial conflict
- Severity 4 null vs positive: Wong 2016 [bundle:24] vs Molani-Gol 2024 [bundle:16]; Molani-Gol 2024 [bundle:16] (positive on body mass index) vs Wong 2016 [bundle:24] (null on body mass index) — partial conflict

## Conclusion

For resveratrol intervention resveratrol supplementation subgroups, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for broad aging-related prevention claims outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## References

- **Li 2021.** _Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials._ BMC Complementary Medicine and Therapies, 2021. DOI: 10.1186/s12906-021-03381-4 PMID: 34420523.
- **Ortiz 2019.** _Recovery Of Bone And Muscle Mass In Patients With Chronic Kidney Disease And Iron Overload On Hemodialysis And Taking Combined Supplementation With Curcumin And Resveratrol._ Clinical Interventions in Aging, 2019. DOI: 10.2147/CIA.S223805 PMID: 31819387.
- **Huang 2021.** _Protective and Recovery Effects of Resveratrol Supplementation on Exercise Performance and Muscle Damage following Acute Plyometric Exercise._ Nutrients, 2021. DOI: 10.3390/nu13093217 PMID: 34579095.
- **Most 2018.** _The effects of polyphenol supplementation on adipose tissue morphology and gene expression in overweight and obese humans._ Adipocyte, 2018. DOI: 10.1080/21623945.2018.1469942 PMID: 29786471.
- **SHEN 2026.** _Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases._ In Vivo, 2026. DOI: 10.21873/invivo.14235 PMID: 41760304.
- **Zhang 2026.** _Resveratrol supplementation mitigates age-related declines in egg production, quality, and ovarian health of laying hens._ Animal Nutrition, 2026. DOI: 10.1016/j.aninu.2025.09.015 PMID: 41938617.
- **Wong 2020.** _Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial._ Journal of Bone and Mineral Research, 2020. DOI: 10.1002/jbmr.4115 PMID: 32564438.
- **Wong 2016.** _Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus._ Nutrients, 2016. DOI: 10.3390/nu8070425 PMID: 27420093.
- **Made 2017.** _Trans -Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants._ Nutrients, 2017. DOI: 10.3390/nu9060596 PMID: 28604618.
- **Ligt 2020.** _No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial._ The American Journal of Clinical Nutrition, 2020. DOI: 10.1093/ajcn/nqaa125 PMID: 32492138.
- **Nikniaz 2023.** _Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail._ BMC Oral Health, 2023. DOI: 10.1186/s12903-023-02877-4 PMID: 36973728.
- **Poulsen 2013.** _High-Dose Resveratrol Supplementation in Obese Men._ Diabetes, 2013. DOI: 10.2337/db12-0975 PMID: 23193181.
- **Zhu 2025.** _The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2024.1463027 PMID: 39872318.
- **Jardon 2024.** _Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity._ Gut Microbes, 2024. DOI: 10.1080/19490976.2024.2392875 PMID: 39182247.
- **Nyambuya 2020.** _A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy._ Molecules, 2020. DOI: 10.3390/molecules25235645 PMID: 33266114.
- **Movahed 2020.** _Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial._ Nutrients, 2020. DOI: 10.3390/nu12010161 PMID: 31935938.
- **Goncalinho 2021.** _Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial._ Molecules, 2021. DOI: 10.3390/molecules26113168 PMID: 34073163.
- **Dzator 2022.** _A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine._ Nutrients, 2022. DOI: 10.3390/nu14091763 PMID: 35565731.
- **Sangouni 2022.** _Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial._ BMC Cardiovascular Disorders, 2022. DOI: 10.1186/s12872-022-02637-2 PMID: 35538431.
- **Sun 2026.** _Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials._ Nutrition Journal, 2026. DOI: 10.1186/s12937-026-01319-5 PMID: 41987155.
- **Zortea 2016.** _Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors._ Nutrients, 2016. DOI: 10.3390/nu8020073 PMID: 26840331.
- **Evans 2016.** _Clinical Evaluation of Effects of Chronic Resveratrol Supplementation on Cerebrovascular Function, Cognition, Mood, Physical Function and General Well-Being in Postmenopausal Women—Rationale and Study Design._ Nutrients, 2016. DOI: 10.3390/nu8030150 PMID: 27005658.
- **Bo 2018.** _Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation._ Acta Diabetologica, 2018. DOI: 10.1007/s00592-017-1097-4 PMID: 29330620.
- **Molani-Gol 2024.** _Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis._ Eur J Nutr, 2024. DOI: 10.1007/s00394-024-03335-9 PMID: 38374352.
- **Farzin 2020.** _No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease._ Int J Vitam Nutr Res, 2020. DOI: 10.1024/0300-9831/a000528 PMID: 30789808.
- **Gorabi 2021.** _Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials._ Phytother Res, 2021. DOI: 10.1002/ptr.7262 PMID: 34472150.
- **Abdollahi 2019.** _The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial._ Phytother Res, 2019. DOI: 10.1002/ptr.6487 PMID: 31475415.
- **Tabrizi 2018.** _The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials._ Food Funct, 2018. DOI: 10.1039/c8fo01259h PMID: 30426122.
- **Bo 2016.** _Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial._ Pharmacol Res, 2016. DOI: 10.1016/j.phrs.2016.08.010 PMID: 27520400.
- **Keramatzadeh 2025.** _Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial._ Nutr Neurosci, 2025. DOI: 10.1080/1028415x.2024.2425649 PMID: 39565038.
- **Russo 2026.** _Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1818450 PMID: 42221760.
- **Faghihzadeh 2015.** _The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study._ Br J Nutr, 2015. DOI: 10.1017/s0007114515002433 PMID: 26234526.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "6c0240ab-e8a1-4e60-b374-f8a79580a148",
  "title": "Research Synthesis: Resveratrol Intervention Resveratrol Supplementation Subgroups \u2014 full paper"
}